News | February 20, 2024
Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
One thousand times more soluble than L-cystine at neutral pH
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Site Enhances New Modality CRDMO Platform Capacity for Customers
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Subscribe To Our Newsletter & Stay Updated
